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Background: An arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis, offering lower morbidity,
mortality, and cost compared with grafts or catheters. Patients with a difficult access extremity have often lost all
superficial veins, and even basilic veins may be obliterated. We have used brachial vein transposition AVFs (BVT-AVFs)
in these challenging patients and review our experience in this report.
Methods: The study reviewed consecutive patients in whom BVT-AVFs were created from September 2006 to March
2009. Most BVT-AVFs were created in staged procedures, with the second-stage transposition operations completed 4
to 6 weeks after the first-stage AVF operation. A single-stage BVT-AVF was created when the brachial vein diameter was
>6 mm.
Results: We identified 58 BVT-AVF procedures, comprising 41 women (71.0%), 28 diabetic patients (48.3%), and 29
(50.0%) had previous access surgery. The operation was completed in two stages in 45 operations (77.6%) and was a
primary transposition in 13 patients. However, five of these were secondary AVFs with previous distal AV grafts or AVFs
placed elsewhere; effectively, late staged procedures. Follow-up was a mean of 11 months (range, 2.0-31.7 months).
Primary patency, primary-assisted patency, and cumulative (secondary) patency were 52.0%, 84.9%, and 92.4% at 12
months and 46.2%, 75.5%, and 92.4% at 24 months, respectively. Harvesting the brachial vein was tedious and more
difficult than harvesting other superficial veins. No prosthetic grafts were used.
Conclusion: BVT-AVFs provide a suitable option for autogenous access when the basilic vein is absent in patients with
difficult access extremities. Most patients required intervention for access maturation or maintenance. Most BVT-AVFs
were created with staged procedures. Cumulative (secondary) patency was 92.4% at 24 months. (J Vasc Surg 2009;50:
1121-6.)The National Kidney Foundation Dialysis Outcomes
Quality Initiative (NKF-KDOQI) and the National Vascu-
lar Access Improvement Initiative (Fistula First) recom-
mend arteriovenous fistulas (AVFs) as the preferred vascu-
lar access for hemodialysis.1,2 AVFs have lower morbidity
and mortality rates in addition to lower yearly Medicare
cost profiles compared with grafts or catheters.3-5 Complex
medical illnesses and previous failed access operations leave
some individuals with a difficult access extremity, confront-
ing surgeons with obliterated cephalic, median antebra-
chial, and basilic veins.6 Brachial vein transposition (BVT)
AVFs (BVT-AVF) have been reported in these challenging
patients with varying results.7-14
We have previously reported our experience with basilic
vein transposition AVFs and our initial experience with
BVT-AVFs.11 This report focuses on our subsequent expe-
rience with BVT-AVFs and reviews other BVT-AVF pub-
lications.
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After receiving approval for this study from our Insti-
tutional Review Board, we analyzed the records of consec-
utive patients in our vascular access database and identified
those who underwent BVT-AVFs constructions by the
communicating author (W. C. J.) from September 2006 to
March 2009. In addition to a physical examination, all
patients underwent preoperative and postoperative ultra-
sound examination by the operating surgeon.15
Most BVT-AVFs were created using staged proce-
dures. Minimum vein diameter for first-stage AVF creation
was 2.5 mm, as measured by ultrasound examination with a
tourniquet in place. The radial artery was used for inflow
when feasible; otherwise, an anastomosis to the brachial
artery was created.6,11,16 Proximal radial artery end-to-side
anastomoses were created through a longitudinal incision
in the antecubital fossa. When the brachial artery was used
for inflow, the size of the anastomosis was limited in rela-
tion to the diameter of the brachial artery, minimizing the
risk of steal syndrome.17
The first-stage AVF was allowed to mature from 4 to 6
weeks before the second-stage transposition of the matured
brachial vein was constructed. Patients were monitored in
the surgical clinic, and the second-stage transposition was
scheduled when the matured outflow vein diameter was
measured by ultrasound to be 6 mm and flow was 300
mL/min.
A single-stage BVT-AVF was created when the brachial
vein diameter was6mm throughout the arm as measured
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actually late staged transpositions because the patients had
been referred after failed forearm grafts or fistulas resulting
in a larger, matured brachial vein.
Paired brachial veins often had a similar diameter at the
site of the first-stage AVF creation. The choice of which
vein to use was made by the surgeon using ultrasound,
selecting the most direct intact channel and largest conduit
throughout the upper arm to the axillary vein. This selec-
tion made later transposition of the mature vein easier and
helped decrease the incidence of developing a dominant
outflow channel encircling the brachial artery that would
require vein division with an end-to-end reanastomosis
later at the second-stage transposition.
The incision for the BVT-AVF was mapped by a brief
ultrasound examination by the surgeon in the operating
room just before the procedure (Fig 1). A longitudinal
incision was used just anterior to the vein position, allowing
a more anterior superficialization of the transposed vein for
ease of cannulation. The fascia and subcutaneous tissue
layers were closed with absorbable interrupted suture be-
fore final positioning of the vein. The transposed vein was
then placed beneath a narrow subcutaneous flap, just ante-
rior to the surgical incision, 3 to 4 mm deep. Interrupted
sutures secured this positioning, thereby avoiding cannula-
tion of the mature vein through the surgical scar. By
mobilizing the mature brachial vein throughout the length
of the upper arm into the axillary vein, adequate length
could be obtained for cannulation, even in obese patients.
We generally allow access cannulation 4 to 6weeks after
transposition. Patent BVT-AVFs in this report could be
used with two needles and met the hemodialysis prescrip-
tion of the nephrologist at the individual dialysis unit.
Primary patency was defined as the time (months) with
uninterrupted patency and without intervention. Primary-
Fig 1. Brief preoperative ultrasound (US) mapping by the sur-
geon confirms the vascular anatomy, surgical plan, and incision site
for the brachial vein transposition-arteriovenous fistula (BVT-
AVF).assisted patency was the time of uninterrupted patencyfrom the original AVF construction where any interven-
tional procedure was necessary. Cumulative (secondary)
patency was the period from the original AVF construction
where AVF patency was interrupted by thrombosis, with or
without AVF salvage, until abandonment of the access or
until completion of the study period.18
Operations were performed in an outpatient setting of
a university-affiliated tertiary medical center. The first- and
second-stage operations were both performed with local
anesthetic and sedation. The transposition operations also
used a regional block anesthetic administered by the sur-
geon through the axillary portion of the incision immedi-
ately on starting the operation with infiltration along the
intercostal brachial, medial brachial cutaneous, and medial
antebrachial cutaneous nerves. Our goal was to create an
autogenous fistula in all patients. CV8 Gore-Tex suture
(W.L. Gore and Associates, Flagstaff, Ariz) was used for
each vascular anastomosis.
Statistical analysis was performed using Prism 4 soft-
ware (GraphPad, San Diego, Calif).
RESULTS
We reviewed the records of 914 consecutive patients in
our vascular access database. From July 2006 to March
2009, 58 BVT-AVFs were constructed by the communi-
cating author (W. C. J.). Mean patient age was 66 years
(range, 17 to 84 years), 41 (71.0%) were women, 28
(48.3%) were diabetic, and 17 (29.3%) were obese. Thirty-
one individuals were African Americans, 25 were white, and
two were American Indian. Twenty-nine patients (50.0%)
had previous access surgery. Mean follow-up was 11
months (range, 2.0-31.7 months). Only seven patients
were referred for vascular access before starting dialysis.
The BVT-AVFs were created in staged procedures in
45 individuals (77.6%) and were primary operations in 13
patients. Five of these primary transpositions were second-
ary AVFs with previous distal AV grafts or AVFs placed
elsewhere; effectively, late-staged procedures. In the re-
maining eight patients, a short basilic vein segment ex-
tended the length of the transposed brachial vein conduit.
The brachial vein comprised most of the transposed seg-
ment in each of these operations.
Mean time to use of staged BVT-AVFs, excluding
late-staged procedures, was 3.4 months (range, 2.0-6.4
months). This included time from the first stage AVF
construction, creation of the staged transposition 4 to 6
weeks later, and eventual final healing, maturation, and
cannulation of the access. Mean time to use of primary
BVT-AVFs was 1.8 months (range, 0.8-3.0 months).
Five patients died during the study period, 2.5 to 11
months after the BVT-AVF of causes unrelated to operative
or access events. Of the patients with failed or nonfunc-
tional BVT-AVFs, one moved and was lost to follow-up,
one changed to peritoneal dialysis, and another declined
further surgery and continued with catheter access. Two
patients had later successful autogenous access operations
in the contralateral arm: one underwent saphenous vein
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received a kidney transplant.
Central venous stenosis caused postoperative arm
swelling in two patients, and both resolved with interven-
tion and functional fistulas were maintained. Arm swelling
was not otherwise encountered and has not been a problem
specific to BVT-AVFs. One patient presented with dialysis
access-associated steal syndrome, which was permanently
resolved and the access maintained by a flow-guided band-
ing procedure. There were no wound infections. Two
patients had small, superficial wound separations that re-
solved promptly. Two other individuals had postoperative
hematomas that delayed access use but required no specific
treatment. No patient required surgery for pseudoaneu-
rysms during the study period.
We strive to use buttonhole access for each BVT-AVF.
Our practice includes a broad range of dialysis patients,
particularly those with past access failures from other areas
and states, explaining the large number of patients who did
not have a superficial or even a basilic vein available for
construction of an autogenous access.19
Eight staged BVT-AVFs required vein division and
end-to-end anastomosis because of a brachial vein position
beneath a nerve or artery. Staged BVT-AVFs were elevated
just anterior to the incision owing to the relatively short
length of the brachial vein, allowing the longest cannula-
tion segment possible. Primary transpositions generally had
more vein length for a subcutaneous tunnel to be created.
AVFs were created in all patients during the study
period, and no grafts were used for vascular access. Proxi-
mal radial artery inflow was used in 16 patients. Primary,
primary-assisted, and cumulative (secondary) patency rates
were 52.0%, 84.9%, and 92.4% at 12 months and 46.2%,
75.5%, and 92.4% at 24 months (Fig 2). Patency rates were
similar for both staged and primary BVT-AVFs.
Balloon angioplasty during a diagnostic fistulogram
Fig 2. Kaplan-Meier analysis of primary (dashed line) as
patency shows the number at risk along curves.was our preferred and most common method of interven-tion. Four patients required surgical revision. Access seg-
ments requiring intervention included the anastomosis, the
body of the transposed vein, and at the swing site or
outflow segment. We did not find a single site to dominate
the areas of nonmaturation.
DISCUSSION
The use of autogenous access for hemodialysis is
broadly supported in the nephrology and surgical litera-
ture.1,2 With the national effort to decrease catheters and
grafts, surgeons will increasingly be confronted with chal-
lenging chronically ill patients in whom superficial veins are
not available. Peripherally inserted central catheters are
common and may obliterate basilic veins. Chronic periph-
eral vascular disease often makes thigh access operations
problematic, leaving BVT-AVFs or translocations of saphe-
nous or femoral veins as alternative autogenous choices.
Schanzer et al7 first reported BVT-AVFs in the English
language literature in 2004, describing two patients with
successful outcomes. Other reports followed and are out-
lined in the Table. Consensus papers and review articles
have recognized BVT-AVFs as autogenous options when
direct AVFs or transpositions of the basilic or cephalic veins
are not feasible.20,21
Spergel et al20 and other authors have commented on
the quality of the brachial vein compared with the basilic
vein, noting the brachial vein to be more fragile and
smaller, in addition to having a shorter overall length
available for superficialization vs the basilic vein. These
observations led some surgeons to use staged transposition
procedures rather than primary (one-stage) operations.
Overall, staged procedures appear to have been more com-
mon and are generally preferred.
In our experience, the brachial vein should be used for
vascular access as a staged procedure unless the diameter is
6 mm. A brachial vein of this size is often the result of
(dotted line), and cumulative (solid line) vascular accesssistedprevious access surgery withmaturation due to previous AV
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ary AVF.22 In a previous report, we described our decision
to stage basilic vein transpositions based on vein size,
reserving primary basilic vein transpositions for those veins
4 mm in diameter.11 However, owing to a difference in
brachial vein quality, length, and depth, we reserve primary
brachial vein transposition for those brachial veins 6 mm
in diameter.
Harvest of the brachial vein for a BVT-AVF can be
challenging. The staged, mature brachial vein is, at times,
densely adherent to the brachial artery and adjacent nerves.
The vein itself is thinner and somewhat more fragile than a
mature basilic or cephalic vein AVF. The brachial vein has
more branches, both large and small, often encircling the
brachial artery to communicate with the paired brachial
vein. In addition, several of these branches are quite short,
requiring meticulous division and closure or repair. A brief
ultrasound examination by the surgeon before the opera-
tion is very useful in clarifying which outflow vein segments
make up the largest and preferred conduit. Although we
did not record operative times in this analysis, we estimate
that BVT-AVF operations may require up to 50% more
time to complete than basilic or cephalic vein transposi-
tions.
We included patients in this analysis with a short seg-
ment of basilic vein contributing a small portion of the total
transposed vein segment. Most often, we found these seg-
mental sections of basilic vein communicated by a large
branch into the brachial vein and the major portion of the
basilic vein had been obliterated. These complex venous
outflow situations are best identified by the operating sur-
geon during an ultrasound examination.
We do not view an interventional procedure as a surgi-
cal failure and immediately obtain a fistulogram if there is
Table. Brachial vein transposition reports for vascular acce
Communicating
author Year
BVT,
No. Primary or staged
Schanzer7 2004 2 Both primary Retr
Angle8 2005 20 All staged Retr
Donobantu9 2006 33 All staged Retr
Elwakeel10 2007 21 All staged Retr
Stembengh14 2008 17 All primary Retr
ba
Angle13 2008 42 “Often” staged Retr
BV
Jemings11 2008 6 All staged Retr
an
Schanzer12 2008 13 11 primary; 2 staged Retr
br
an
BVT, Brachial vein transposition; VT, vein transposition.any question of access dysfunction. Although we do nothave a formal postsurgical screening program, access prob-
lems noted in the dialysis unit, such as inadequate inflow,
high venous pressures, prolonged bleeding, recirculation,
difficult cannulation, and other issues, generate a surgical
evaluation and ultrasound examination with a fistulogram
and intervention as warranted. Interventional procedures
will be necessary in a significant number of patients for
maturation and maintenance of a successful fistula.
Limitations of this study include the retrospective de-
sign and that a single-surgeon experience is reported.
CONCLUSIONS
Brachial vein transposition AVFs provide a suitable
option for autogenous access when the basilic vein is absent
in patients with difficult access extremities. Most patients
required intervention for access maturation or mainte-
nance. Most BVT-AVFs were created with staged proce-
dures. Cumulative (secondary) patency was 92.4% at 24
months. Harvest of the brachial vein for transposition is
challenging and often more time consuming than transpo-
sition of other veins.
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Dr Harry Schanzer (New York, NY). As Dr Jennings men-
tioned, we described the use of the brachial vein for AV [arterio-
venous] fistula 5 years ago; and 2 years ago we presented and pub-
lished our experience in a series of 13 patients. We did the procedure
in one stage because we had such good results with the basilic vein
transposition AV fistula performed in one stage. Our results at 1 year
were a primary patency rate of 24%, assisted primary patency of 45%,
and a secondary patency rate of 45%. Their outcomes were signifi-
cantly worse than the ones obtained with AV graft; and therefore, we
concluded that this AV fistula, when done in one stage, should not
replace an AV graft. Since then, there have been at least two other
papers besides the series just presented by Dr Jennings that showed
that the use of the brachial vein AV fistula, when performed in two
stages, has significantly better results. So I think that a very important
message is that if you are going to use the brachial vein as a source for
AV fistula, do it in two stages.
I have two questions. You have said that when you have a vein
that is larger than 6 mm, you use it in one stage. I would like to
know, what is the patency rate in these one-stage procedures? And
second, how do you measure the diameter? Do you measure
pre-op by duplex? Do you measure it in the operating room when
you expose the vein? Do you measure it when you have dilated the
vein after it’s already exposed?
Dr William C. Jennings. Patency for the primary operations
was not significantly different from the staged operations, but the
veins were larger. At least half of the few primary transpositions we
did were, in effect, late staged, because they had either had a
forearm graft or a fistula elsewhere when they came to us. The
other primary transpositions were all short segment basilic veins
entering a larger brachial vein, but still the main length of theof the vein preoperatively with ultrasound and with a tourniquet in
place, and I think that is generally the standard.
Dr Schanzer. I think that this is important. In the basilic
vein that enters in the upper arm, that is really, I think, a basilic
vein transposition with some proximal brachial vein. The other
ones that you are mentioning had already mature brachial vein
by the distal AV fistula prior. So I think that the problem with
the brachial vein is that it is a different vein than the basilic vein
in terms of being very thin, multiple little branches that go
around the brachial vein that you have to meticulously dissect.
It is very easy to torque the vein when you pass it in the tunnel,
and I think that that is why the patency rate is much more
inferior than in two stages.
Dr Salaheddine Tomeh (Phoenix, Ariz). Are you using the
brachial vein for an AV fistula, as a primary choice, in the presence
of superficial veins, such as a cephalic vein, or a secondary choice
when superficial veins are not available?
Dr Jennings. We use the brachial vein only when all other
superficial veins and the basilic veins have been exhausted.
Dr Tomeh. In that situation then, the venous outflow of the
whole arm is limited. How much swelling or venous hypertension
is created by using the brachial vein?
Dr Jennings. This is a frequent question, and swelling has
not been a problem. If you have central venous occlusion or
stenosis, as with any access, radiocephalic or anything else, you
may have arm swelling. But in the absence of central venous
stenosis or occlusion, we don’t see significant or long-term
swelling. There are the other paired brachial veins, muscular
veins, and other venous channels that pick up the outflow.
Dr Joseph Schneider (Winfield, Ill). I’d like to just challenge
you a little bit more. I have done over 500 transposed basilics in the
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three times. I am just curious about how you found so many
patients that didn’t have an adequate basilic vein, unless you did
5000 transposed basilics.
Dr Jennings. My practice is generally mostly vascular access
and we see patients frommany different areas that have already had
exhausted other sites. I search for a basilic vein in these patients and
that is by far my preferred choice. This is generally the final upper
extremity option for autogenous access. We just see many of these
patients without other vein options.
Dr William Cohen (Los Angeles, Calif). This pertains to a
staged procedure. When you do the anastomosis, it is important to
ligate all the tributaries of the brachial vein in the area. If you do
not, and perform an AVG later on because of inadequate brachial
vein development, these tributaries may have enlarged, and be
difficult to approach because of scar tissue. A significant steal may
result.Dr Jennings. I completely agree with you but for other
reasons, too. I try to stay out of the small first-stage operative field,
so I ligate all side branches up to where the new incision will be for
the transposition 4 to 6 weeks later. You want all the AVF outflow
to go into the transposed vein.
Dr Domenico Valenti (London, United Kingdom). Can you
tell me about the functional patency of your series?
Dr Jennings. These have been functional fistulas and used for
dialysis if they are not listed as failures.
Dr Valenti. Can you tell me, what is your mean cannulation
time?
Dr Jennings. I don’t have that exact number. But we generally
allow them to be cannulated at 4 weeks. Some end up being 2
months, but we try to use them promptly. We evaluate the fistula
using ultrasound for access flow and vein diameter and mark the vein
before they go back to the dialysis unit. So if we can’t cannulate the
fistula we’ll get a fistulogram and intervention if needed.
